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Section	S1:	Collaborators	
 
Sites	in	which	study	was	open	to	recruitment,	numbers	of	men	recruited	(n)	and	key	
contributors	from	site:	
	
Helsinki	University	Hospital,	Finland	(74):	Antti	S.	Rannikko,	Anu	Kenttämies,	Tuomas	Mirtti.	
	
Centro	de	Urologia	CDU,	Argentina	(64):	Marcelo	Borghi,	Edgardo	F.	Becher.	
	
Sapienza	University,	Italy	(61):	Valeria	Panebianco,	Carlo	Catalano,	Marcello	Grompone,	
Maurizio	Del	Monte,	Leonardo	Costantino,	Alessandro	Sciarra,	Giuseppe	D’	Eramo,	Vincenzo	
Salvo,	Riccardo	Campa.	
	
Mayo	Clinic,	Rochester,	MN,	USA	(54):	Lance	A.	Mynderse,	Bernard	F.	King,	Adam	T.	
Froemming,	Robert	H	McLaren,	Pamela	J.	Draayer,	Jane	E.	Smith,	Kathryn	J.	Doty.		
	
MRC	Oulu,	University	of	Oulu	and	Oulu	University	Hospital,	Oulu,	Finland	(53):	Markku	H.	
Vaarala,	Panu	Tonttila,	Ville	Virta,	Mari	Kuisma,	Eija	Pääkkö,	Pasi	Hirvikoski.	
	
San	Raffaele	Hospital,	Italy	(51):	Alberto	Briganti,	Francesco	Montorsi,	Armando	Stabile,	
Francesco	De	Cobelli,	Antonio	Esposito,	Marta	Picozzi,	Giulia	Cristel,	Giorgio	Brembilla.		
	
University	College	London	and	University	College	London	Hospital,	UK	(21):	Veeru	
Kasivisvanathan,	Michelle	Hung,	Frelyn	Ocampo,	Marjorie	Otieno,	Navin	Ramachandran,	
Doug	Pendse,	Shonit	Punwani,	Alex	Kirkham,	Francesco	Giganti,	Clare	Allen,	Alex	Freeman,	
Charles	Jameson,	Marzena	Ratynska,	Imen	Ben-Salha,	Mark	Emberton,	Caroline	M.	Moore.		
	
Martini	Klinik,	Hamburg,	Germany	(20):	Lars	Budäus,	Sami-Ramzi	Leyh-Bannurah.	
	
London	North	West	Healthcare	NHS	Trust,	UK	(13):	Giles	Hellawell,	Anthony	Chambers,	
Byiravey	Pathmanathan,	Wade	Gayed,	Eirini	Vrentzou,	Rachel	Baldwin.	
	
Hampshire	Hospitals	NHS	Foundation	Trust,	UK	(12):	Richard	G.	Hindley,	Govinder	Rajkumar,	
Amr	Emara,	Tim	Nedas,	Abigail	Edwards.	
	
Erasmus	University	Medical	Center,	Rotterdam,	the	Netherlands	(12):	Monique	J.	Roobol,	
Chris	H.	Bangma,	Martijn	B.	Busstra,	Ivo	G.	Schoots.	
	
University	of	Chicago,	USA	(9):	Scott	Eggener,	Aytekin	Oto,	Glenn	Gerber.	
	
Whittington	Health	NHS	Trust,	UK	(9):	Maneesh	Ghei,	Taimur	Shah,	Sami	Hamid,	Paul	
Erotocritou,	Barry	Maraj,	Jeevan	Kumaradeevan.	
	
CHU	Lille,	France	(9):	Arnauld	Villers,	Philippe	Puech,	Jonathan	Olivier.	
	
Jewish	General	Hospital,	Montreal,	Canada	(8):	Franck	Bladou,	Oleg	Loutochin.	
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Ghent	University	Hospital,	Belgium	(5):	Geert	M.	Villeirs,	Pieter	De	Visschere,	Nicolaas	
Lumen,	Marleen	Praet.	
	
Princess	Alexandra	Hospital	NHS	Trust,	UK	(4):	Jaspal	Virdi,	Manit	Arya.	
	
University	Hospital	Bern,	Switzerland	(4):	Silvan	Boxler,	Harriet	Thoeny.	
	
Bordeaux	Pellegrin	University	Hospital,	France	(4):	Grégoire	Robert,	Clément	Michiels,	Yann	
Lebras.	
	
Royal	Free	London	NHS	Foundation	Trust,	UK	(4):	Paras	B.	Singh,	Gillian	Smith,	Lee	Grant,	
Antony	Goode,	Soha	El	Sheikh.	
	
Radboudumc,	the	Netherlands	(4):	Wulphert	Venderink,	Jurgen	J	Fütterer,	JP	Michiel	
Sedelaar.	
	
University	Hospital	Heidelberg	and	German	Cancer	Research	Center,	Heidelberg,	Germany	
(3):	Boris	A.	Hadaschik,	Jan	P.	Radtke,	Markus	Hohenfellner,	David	Bonekamp,	Heinz-Peter	
Schlemmer.	
	
Hospices	Civils	de	Lyon,	Centre	Hospitalier	Lyon	Sud,	France	(2):	Alain	Ruffion,	Olivier	
Rouvière.	
	
Weill	Cornell	Medicine	New	York-Presbyterian	Hospital,	USA	(0):	Jim	C.	Hu,	Daniel	Margolis.	
	
Hospices	Civils	de	Lyon	of	the	Hôpital	Edouard	Herriot,	France	(0):	Sébastien	Crouzet.	
	
Other	key	contributing	teams	and	key	contributors:	
	
Data	Monitoring	Committee:	Patrick	Magill,	David	Elkin,	Norman	R.	Williams.	
	
Statistical	analysis,	preparation	and	implementation:	Yemisi	Takwoingi,	Fatima	Jichi,	Richard	
Simon,	Jonathan	Deeks.	
	
Trial	coordination	and	operations:	University	College	London	Surgical	and	Interventional	
Trials	Unit:	Chris-Brew	Graves,	Samim	Patel,	Ingrid	Potyka,	Neil	McCartan,	Cinzia	Baldini,	
Jack	Grierson.		
	
Health	economics:	Stephen	Morris	
	
Quality	control	team:	Francesco	Giganti,	Clare	Allen,	Alex	Freeman,	Charles	Jameson,	
Marzena	Ratynska,	Imen	Ben-Salha,	Aiman	Haider.	
	
Electronic	case	report	form	team:	European	Association	of	Urology	Research	Foundation:	
Christien	Caris,	Joke	van	Egmond,	Wim	Witjes,	Peter	Mulders,	Anders	Bjartell.	
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Section	S2:	Further	details	on	statistical	methods	
	
We	used	Stata	version	15	and	SAS	version	9.4	for	the	analyses	of	primary	and	secondary	
outcomes.	We	conducted	intention-to-treat	analyses	for	all	secondary	outcomes	as	outlined	
below	(see	list	of	outcomes	in	Table	S6).		
	
Proportion	of	men	with	clinically	insignificant	cancer	detected	
Clinically	insignificant	cancer	was	defined	as	Gleason	grade	3+3	disease.		We	fitted	a	
generalized	linear	mixed	model	with	the	clinically	insignificant	cancer	binary	outcome	as	the	
dependent	variable,	arm	as	an	independent	variable	and	center	as	a	random	effect.	We	
used	this	model	to	estimate	an	adjusted	absolute	difference	in	detection	rates	(i.e.	risk	
difference)	by	using	an	identity	link	function	with	a	binomial	distribution.			
	
Proportion	of	men	in	the	MRI±TB	arm	who	avoid	biopsy		
We	calculated	the	number	of	men	in	the	MRI±TB	arm	in	whom	there	was	no	suspicion	of	
clinically	significant	cancer	(PIRADSv2	score	≤2	and	so	biopsy	avoided)	divided	by	the	total	
number	of	men	in	the	arm.		
	
Proportion	of	men	in	whom	the	PIRADSv2	score	for	suspicion	of	clinically	significant	
cancer	was	3,	4	or	5	but	no	clinically	significant	cancer	was	detected		
We	calculated	the	proportion	of	men	who	underwent	biopsy	in	the	MRI±TB	arm	but	in	
whom	no	clinically	significant	cancer	was	detected.		
	
Proportion	of	men	who	go	on	to	definitive	local	or	systemic	treatment		
Treatment	for	prostate	cancer	may	include:	
•	 Active	surveillance		
•	 Radical	prostatectomy		
•	 Radical	radiotherapy		
•	 Radical	brachytherapy	
•	 Focal	therapy		
•	 Hormone	therapy		
We	calculated	the	proportion	of	men	in	each	arm	who	underwent	each	treatment.		
	
Proportion	of	Gleason	grade	upgrading	in	men	undergoing	radical	prostatectomy	
Of	the	men	who	underwent	radical	prostatectomy,	the	proportion	of	men	who	had	cancer	
upgraded	from	the	biopsy	histopathology	to	the	radical	prostatectomy	histopathology	in	
each	arm	was	calculated	and	tabulated.		
	
Proportion	of	men	with	post-biopsy	adverse	events		
Immediate	post-biopsy	discomfort	and	pain	were	characterized	by	intensity	using	the	
numerical	analogue	score	and	scores	for	each	arm	were	summarised.	30-day	biopsy	specific	
complications	and	adverse	events	were	characterized	according	to	their	presence,	absence,	
duration	and	how	much	of	a	problem	the	symptoms	caused	the	participant.	Whether	the	
participant	had	contact	with	health	care	was	also	recorded.	The	proportion	of	individuals	
experiencing	each	symptom,	proportion	in	whom	the	symptom	caused	a	problem	and	
proportion	who	had	contact	with	healthcare	were	ascertained.		The	biopsy	specific	
complications	that	were	assessed	included	pain,	urinary	retention,	fever,	pain,	erectile	
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dysfunction,	urinary	incontinence,	haematuria,	haematochezia	and	haemotospermia.	Any	
post-biopsy	complications	up	to	30	days	post	biopsy	procedure	was	tabulated	and	listed	by	
duration	and	management.	
	
Cancer	core	length	of	the	most	involved	biopsy	core	
The	mean	maximum	cancer	core	length	from	each	arm	was	compared	using	mixed	effects	
linear	regression	with	maximum	cancer	core	length	as	the	dependent	variable,	arm	as	an	
independent	variable	and	center	as	a	random	effect.		
	
Health-related	quality	of	life	scores	
EQ-5D-5L	descriptive	domain	summary	indices	and	visual	analogue	scores	were	assessed	at	
baseline,	and	24	hours	and	30	days	post	intervention.	Scores	from	the	5	domains	of	the	
questionnaire	were	converted	to	EQ-5D	descriptive	scores	using	the	value	set	for	the	United	
Kingdom.	To	estimate	mean	differences	between	arms,	each	outcome	was	analysed	using	a	
repeated-measures	mixed	model	with	adjustment	for	baseline	levels	of	the	outcome	
variable.	Only	men	who	fully	completed	a	questionnaire	were	included	in	the	analyses.	
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Section	S3:	Adjustment	for	multiple	secondary	outcomes	
	
In	post-hoc	analyses	following	NEJM	guidance,	the	Bonferroni	correction	was	used	to	adjust	
the	standard	threshold	for	statistical	significance	for	the	three	secondary	outcomes:	
proportion	of	clinically	insignificant	cancer,	maximum	core	length	and	health-related	quality	
of	life.	A	two-sided	P	value	of	less	than	0.017(i.e.,	0.05/3)	was	used	to	indicate	statistical	
significance	instead	of	the	conventional	0.05	value.		
	
Using	the	0.05	threshold	the	difference	in	health-related	quality	of	life	between	MRI±TB	and	
TRUS	biopsy	was	not	statistically	significant	at	24	hours	and	30	days	post	intervention	(Table	
S10)	and	so	inferences	remain	unchanged	after	adjustment	for	multiplicity.		
	
Similarly,	for	the	difference	in	maximum	cancer	core	length,	the	P	value	was	0.053	(see	
Table	2)	and	is	not	statistically	significant	either	at	the	standard	critical	value	of	0.05	or	the	
adjusted	value	of	0.017.		
	
For	the	difference	in	clinically	insignificant	cancer,	the	results	remain	statistically	significant	
(P<0.001)	whichever	threshold	it	was	compared	to.	
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Figure	S1:	Trial	Schema1	
 
	
	 	
Visit	1	-	Randomization	(n≥470),	1:1	allocation	
Visit	4:	Test	results	given	&	Treatment	decision	
Final	Questionnaires	
Follow	up	for	further	investigations	or	radical	prostatectomy	
Visit	2:	Multi-parametric	MRI	
Arm	1:	(n≥235)	
 
Arm	2:	(n≥235)	
 
Visit	3:	MRI-targeted	
biopsy	of	the	prostate	
Visit	3:	10-12	core	trans-rectal	biopsy	
of	the	prostate	
Man	with	no	prior	biopsy	referred	with	clinical	suspicion	of	prostate 
cancer  
MRI	score	1,2	 MRI	score	3,4,5	
No	biopsy	
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Table	S1:	Recruitment	by	site	
	
Table	8:	Recruitment	by	centre	
Centre	 MRI±TB	
	
TRUS-biopsy	 Total	
Helsinki	University	Hospital,	Finland	 37	 37	 74	
Centro	de	Urologia	CDU,	Argentina	 31	 33	 64	
Sapienza	University,	Italy	 31	 30	 61	
Mayo	clinic,	Rochester,	Minnesota,	USA	 27	 27	 54	
Oulu	University	Hospital,	Finland	 27	 26	 53	
San	Raffaele	Hospital,	Italy	 26	 25	 51	
University	College	London	Hospitals	NHS	
Foundation	Trust,	UK	 10	 11	 21	
Martini	Klinik,	Hamburg,	Germany	 10	 10	 20	
London	North	West	Healthcare	NHS	Trust,	UK	 7	 6	 13	
Erasmus	University	Medical	Center,	Rotterdam,	the	
Netherlands	 6	 6	 12	
Hampshire	Hospitals	NHS	Foundation	Trust,	UK	 6	 6	 12	
CHU	Lille,	France	 4	 5	 9	
University	of	Chicago,	USA	 5	 4	 9	
Whittington	Health	NHS	Trust,	UK	 5	 4	 9	
Jewish	General	Hospital,	Montreal,	Canada	 4	 4	 8	
Ghent	University	Hospital,	Belgium	 3	 2	 5	
Bordeaux	Pellegrin	University	Hospital,	France	 2	 2	 4	
Princess	Alexandra	Hospital	NHS	Trust,	UK	 2	 2	 4	
RadboudUMC,	the	Netherlands		 2	 2	 4	
Royal	Free	London	NHS	Foundation	Trust,	UK	 2	 2	 4	
University	Hospital	Bern,	Switzerland	 2	 2	 4	
University	Hospital	Heidelberg,	Germany	 2	 1	 3	
Hospices	Civils	de	Lyon,	Centre	Hospitalier	Lyon	
Sud,	France	 1	 1	 2	
Weill	Cornell	Medicine	New	York-Presbyterian	
Hospital,	USA	 0	 0	 0	
Hospices	Civils	de	Lyon	of	the	Hôpital	Edouard	
Herriot,	France	 0	 0	 0	
Total	 252	 248	 500	
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Table	S2:	Eligibility	criteria	for	enrollment1			
 
Inclusion	criteria:	
1. Men	at	least	18	years	of	age	referred	with	clinical	suspicion	of	prostate	cancer	who	
have	been	advised	to	have	a	prostate	biopsy	
2. Serum	PSA	≤	20ng/ml		
3. Suspected	stage	≤	T2	on	rectal	examination	(suspected	organ-confined	prostate	
cancer)		
4. Fit	to	undergo	all	procedures	listed	in	protocol	
5. Able	to	provide	written	informed	consent	
	
Exclusion	criteria:	
1. Prior	prostate	biopsy	
2. Prior	treatment	for	prostate	cancer	
3. Contraindication	to	MRI	(e.g.	claustrophobia,	pacemaker,	estimated	GFR	≤	50mls/min)		
4. Contraindication	to	prostate	biopsy		
5. Men	in	whom	artefact	would	reduce	the	quality	of	the	MRI	
6. Previous	hip	replacement	surgery,	metallic	hip	replacement	or	extensive	pelvic	
orthopaedic	metal	work		
7. Unfit	to	undergo	any	procedures	listed	in	protocol	
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Table	S3:	MRI	protocols		
Site	 1	 2	 3	 4	 5	 6	 7	 7	 8	
MRI	manufacturer	 Philips	 Philips	 GE	 GE	 Siemens	 Philips	 Siemens	 Philips	 Philips	
MRI	Model	 Achieva	 Ingenia	 Discovery	 Discovery		 Skyra	 Achieva	 Avanto	 Achieva	 Ingenia	
Field	Strength	 3T	 3T	 3T	 3T	 3T	 1.5T	 1.5T	 3T	 3T	
Coils	 PPA	 PPA	 PPA	&	ER	 PPA	 PPA	 PPA	&	ER	 PPA	 PPA	 PPA	
Sequences	used	 T2,	DWI,	DCE	 T2,	DWI,	DCE	 T2,	DWI,	DCE	 T2,	DWI,	DCE	 T2,	DWI,	DCE	 T2,	DWI,	DCE	 T2,	DWI,	DCE	 T2,	DWI,	DCE	 T2,	DWI,	DCE	
T2	sequence	details	
Planes	acquired	
			
Slice	Thickness	(axial)	
Voxel	size	(axial)	
	
Axial,	coronal,	
sagittal	
3mm	
0.389	x	0.389	x	
3	mm	
	
Axial,	coronal,	
sagittal	
3mm	
0.352	x	0.352	
x	3	mm	
	
Axial,	coronal,	
sagittal	
3mm	
0.435	x	0.435	
x	3	mm	
	
Axial,	coronal,	
sagittal	
3mm	
0.469	x	0.469	
x	3	mm	
	
Axial,	coronal,	
sagittal	
3mm	
0.521	x	0.521	
x	3.3mm	
	
Axial,	coronal,	
sagittal	
3mm	
0.312	x	0.312	
x	3	mm	
	
Axial,	coronal	
	
3mm	
0.391	x	0.391	
x	3.45	mm	
	
Axial,	coronal	
	
3mm	
0.375	x	0.375	
x	3.3mm	
	
Axial,	coronal,	
sagittal	
3mm	
0.37x0.37x3mm	
DCE	sequence	details	
Temporal	resolution	
Model	used	for	post-	
processing	
Slice	Thickness	
Voxel	size	
			
Power	Injector	
		Gadolinium	contrast	
		Injection	rate	
		Flush	given	after	
Fat	saturation	
(FS)/subtraction(SUB)	
	
6.91	s	
DynaCAD	
	
4mm	
0.75	x	0.75	x	
4mm	
Yes	
Dotarem	
3mls/s	
Yes	
	
Yes	(FS)	
	
10	s	
DynaCAD	
	
3	mm	
1.3	x	1.3	x		
3mm	
Yes	
Gadovist	
1ml/s	
Yes	
	
No	
	
5	s	
genIQ	
	
1.5	mm	
1.02	x	1.02	x	
1.5mm	
Yes	
Gadovist	
3mls/s	
Yes	
	
Yes	(FS)	
	
6.5	s	
DynCAD	
	
3mm	
0.859	x	0.859	
x	3mm	
Yes	
Dotarem	
3mls/s	
Yes	
								
No	
	
7.4	s	
NR	
	
3.6mm	
1.35	x	1.35	x	
3.6mm	
Yes	
Dotarem	
2.5mls/s	
Yes	
	
No	
	
9	s	
NR	
	
3mm	
0.625	x	0.625	
x	3mm	
Yes	
Gadobutrol	
2mls/s	
Yes	
	
Yes	(FS)	
	
11	s	
No	
	
3mm	
0.677	x	0.677	
x	3mm	
Yes	
Dotarem	
3mls/s	
Yes	
	
Yes	(FS)	
	
11	s	
No	
	
3mm	
0.938	x	0.938	
x	3mm	
Yes	
Dotarem	
3mls/s	
Yes	
	
Yes	(FS)	
	
3.2s		
DynaCAD	
	
3mm	
1.02	x	1.02	
x3mm	
Yes	
Dotarem	
NR	
NR	
	
No	
DWI	sequence	details	
B-values	used	
			
ADC	threshold	
applied?	
			
DWI	combinations	
	
Slice	Thickness		
Voxel	size	
	
0,100,800,	
2000	
No	
	
Multi-b	value,	
ADC	&	high	b	
	
3mm	
0.893	x	0.893	x	
3mm	
	
0,800,1600	
	
No	
	
Multi-b	value,	
ADC	&	high	b	
	
3mm	
1.47	x	1.47	x	
3mm	
	
0,500,1000,	
3000	
Yes	
	
Multi-b	value,	
ADC	&	high	b	
	
3mm	
0.892	x	0.892	
x	3	mm	
	
100,1000,1600	
	
No	
	
Multi-b	value,	
ADC	&	high	b	
	
6mm	
1.02	x	1.02	x	6	
mm	
	
50,400,800,	
1500,	3000	
No	
	
Multi-b	value,	
ADC	&	high	b	
	
5mm	
1.98	x	1.98	x	
5.2	mm	
	
50,800,1600	
	
No	
	
Multi-b	value,	
ADC	&	high	b	
	
3mm	
1.25	x	1.25	x	
3.3	mm	
	
0,150,500,	
1000,1400	
Yes	
	
Multi-b	value,	
ADC	&	high	b	
	
5mm	
1.51	x	1.51	x	5	
mm 
	
0,150,500,	
1000,2000	
Yes	
	
Multi-b	value,	
ADC	&	high	b	
	
5mm	
0.98	x	0.982	x	
5	mm	
	
0,50,1200	
	
No	
	
Multi-b	value	&	
ADC	
	
3mm	
1.02x1.02x3mm	
Bowel	Relaxant	 Yes	 Yes	 Yes	 Yes	 No	 Yes	 Yes	 Yes	 Yes	
PPA		=	pelvic	phased	array,		ER	=	endorectal,	Res.	=	resolution,	DCE	=	dynamic	contrast	enhanced,	DWI	=	diffusion	weighted	imaging,	s	=	second,	NR	=	not	reported	
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Table	S3:	MRI	protocols	(continued…)	
Site	 9	 10	 11	 12	 13	 14	 15	 16	
MRI	manufacturer	 Philips	 GE	 Siemens	 Philips	 Philips	 Philips	 Siemens	 Siemens	
MRI	Model	 Achieva	 Discovery	 Aera	 Ingenia	 Ingenia	 Achieva	 Skyra	 Trio	
Field	Strength	 1.5T	 3T	 1.5T	 1.5T	 3T	 1.5T	 3T	 3T	
Coils	 PPA	 PPA	 PPA	 PPA	 PPA	&	ER	 PPA	 PPA	 PPA	
Sequences	used	 T2,	DWI,	DCE	 T2,	DWI,	DCE	 T2,	DWI,	DCE	 T2,	DWI,	DCE	 T2,	DWI,	DCE	 T2,	DWI,	DCE	 T2,	DWI,	DCE	 T2,	DWI,	DCE	
T2	sequence	details	
Planes	acquired	
				
Slice	Thickness	(axial)	
Voxel	size	(axial)	
	
Axial,	coronal,	
sagittal	
3mm	
0.417x0.417x	
3.3mm	
	
Axial,	sagittal	
	
3mm	
0.371	x	0.371	
x3.3mm	
	
Axial,	coronal,	
sagittal	
3mm	
0.781x0.781x	
3.3mm	
	
Axial,	coronal,	
sagittal	
3mm	
0.511x0.511	
x3mm	
	
Axial,	coronal	
	
3	mm	
0.45x0.45	
x3mm	
	
Axial,coronal,	
sagittal	
3mm	
0.703x0.703	
x3.3mm	
	
Axial,	coronal,	
sagittal	
3mm	
0.625x0.625	
x3mm	
	
Axial,coronal,	
sagittal	
3mm	
0.512x0.512	
x3mm	
DCE	sequence	details	
Temporal	resolution	
Model	used	for	post-			
processing	
Slice	Thickness	
Voxel	size	
			
Power	Injector	
		Gadolinium	contrast	
		Injection	rate	
		Flush	given	after	
Fat	saturation	
(FS)/subtraction(SUB)	
	
18s	
NR	
	
1.5mm	
0.488x0.488	
x1.25mm	
No	
Dotarem	
3mls/s	
Yes	
	
Yes	(FS)	
	
4-5s	
No	
	
4mm	
1.33x1.33	
x1.5mm	
Yes	
Dotarem	
3mls/s	
Yes	
	
Yes	(FS)	
	
17s	
No	
	
3mm	
0.875x0.875x	
3mm	
Yes	
Dotarem	
3mls/s	
Yes	
	
Yes	(FS)	
	
15s	
Tofts	
	
3mm	
0.625x.0.625	
x3mm	
Yes	
Gadovist/Dotarem	
2mls/s	
Yes	
	
No	
	
7s	
No	
	
1.5mm	
0.994x0.994	
x1.5mm	
Yes	
Multihance/Dotarem	
2mls/s	
No	
	
Yes	(FS)	
	
12	s	
No	
	
3mm	
1.45x1.45	
x3mm	
Yes	
Gadovist	
3mls/s	
Yes	
	
Yes	(FS)	
	
9.2s	
No	
	
3mm	
1.25x1.25x3.1mm	
	
Yes	
Optimark/Omniscan	
2.5mls/s	
Yes	
	
Yes	(FS)	
	
9s	
No	
	
3.6mm	
1.35x1.88x3.6mm	
	
No	
Omniscan	
3mls/sec	
Yes	
	
No	
DWI	sequence	details	
	B-values	used	
			
	ADC	threshold								
	applied?	
	DWI	combinations	
			
			
Slice	Thickness		
	
Voxel	size	
	
0,500,1000,	
1400	
No	
	
Multi-b	value,	
ADC	&	high	b	
	
4.5mm	
	
0.977x0.977x	
4.5	mm	
	
50,400,800	
	
Yes	
	
Multi-b	value	
&	ADC	
	
3mm	
	
0.703x0.703x	
3.3mm	
	
0,150,500,	
1000,	1400	
Yes	
	
Multi-b	value,	
ADC	&	high	b	
	
5mm	
	
1.72x1.72x	
5mm	
	
1,150,1000,2000	
	
No	
	
Multi-b	value	&	
ADC	
	
4mm	
	
1.39x1.39x	
4mm	
	
0,50,150,990,1500	
	
No	
	
Multi-b	value	&	ADC	
	
	
3mm	
	
1.12x1.12x3mm	
	
0,100,500,	
1000,1400	
Yes	
	
Multi-b	value,	
ADC	&	high	b	
	
5mm	
	
1.3x1.3	
x5.5mm	
	
50	,1400	
	
No	
	
Multi-b	value,	ADC	
&	high	b	
	
4mm	
	
1.69x1.69x4mm	
	
	
50,400,800,	
1200,1600	
No	
	
Multi-b	value,	
ADC	&	high	b	
	
3mm	
	
1.62x2.14x3mm	
Bowel	Relaxant	 No	 Yes	 Yes	 Yes	 Yes	 Yes	 No	 Yes	
PPA		=	pelvic	phased	array,		ER	=	endorectal,	Res.	=	resolution,	DCE	=	dynamic	contrast	enhanced,	DWI	=	diffusion	weighted	imaging,	s	=	second,	NR	=	not	reported	
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Table	S3:	MRI	protocols	(continued…)	
Site	 17	 18	 19	 20	 21	 22	 23	
MRI	manufacturer	 Siemens	 Siemens	 Siemens	 Philips	 Siemens	 Siemens	 GE	
MRI	Model	 Avanto	 Avanto	 Skyra	 Ingenia	 Skyra	 Prisma	 Discovery	
Field	Strength	 1.5T	 1.5T	 3T	 1.5T	 3T	 3T	 3T	
Coils	 PPA	 PPA	 PPA	 PPA	 PPA	 PPA	 PPA	
Sequences	used	 T2,	DWI,	DCE	 T2,	DWI,	DCE	 T2,	DWI,	DCE	 T2,	DWI,	DCE	 T2,	DWI,	DCE	 T2,	DWI,	DCE	 T2,	DWI,	DCE	
T2	sequence	details	
Planes	acquired	
			
Slice	Thickness	(axial)	
Voxel	size	(axial)	
	
Axial,	coronal,	sagittal	
	
3.5mm	
0.5x0.5x3.5mm	
	
Axial,	coronal,	
sagittal	
3mm	
0.43x0.43	
x3.3mm	
	
Axial,coronal,	
sagittal	
3mm	
0.5x0.5	
x3.6mm	
	
Axial,coronal,	
sagittal	
3mm	
0.45x0.45	
x3.3mm	
	
Axial,	coronal	
	
3	mm	
0.43x0.43x3	
mm	
	
Axial,coronal,	
sagittal	
3mm	
0.312x0.312	
x3mm	
	
Axial,	sagittal	
	
3mm	
0.43x0.43x	
3mm	
DCE	sequence	details	
Temporal	resolution	
Model	used	for	post-	processing	
Slice	Thickness	
Voxel	size	
			
Power	Injector	
		Gadolinium	contrast	
		Injection	rate	
		Flush	given	after	
Fat	saturation	
(FS)/subtraction(SUB)	
	
9.6s	
NR	
3.5mm	
1.3x1.0x3.5mm	
	
Yes	
Dotarem/Gadovist	
3mls/s	
Yes	
	
Yes	(FS)	
	
14s	
No	
3.5mm	
1.4x1.0x3.5mm	
	
Yes	
Dotarem	
3mls/s	
Yes	
	
NR	
	
3.27s	
proCAD	
3mm	
0.857x0.857	
x3mm	
Yes	
Dotarem	
2.5mls/s	
Yes	
	
No	
	
3.3s	
No	
2mm	
1.42x1.42x2mm	
	
Yes	
Dotarem	
3mls/s	
Yes	
	
Yes	(FS)	
	
3.47s	
No	
3.5mm	
1.38x1.38x	
3.5mm	
Yes	
Multihance	
2.5mls/s	
Yes	
	
No	
	
4.42s	
Tofts	
1.2mm	
1.19x1.19	
x1.2mm	
No	
Gadovist	
3mls/s	
No	
	
Yes	(FS)	
	
6s	
No	
3mm	
0.938x0.938	
x3mm	
Yes	
Gadoterate	
3mls/s	
Yes	
	
Yes	(FS)	
DWI	sequence	details	
		B-values	used	
			
			
ADC	threshold				
		applied?	
		
	DWI	combinations	
			
			
Slice	Thickness		
		
Voxel	size	
	
0,100,800,1500	
	
	
Yes	
	
	
Multi-b	value,	ADC	&	
high	b	
	
3.5mm	
	
1.8x1.4x3.5mm	
	
50,500,1000,	
1350	
	
No	
	
	
Multi-b	value,	
ADC	&	high	b	
	
4mm	
	
2.45x2.45x4mm	
	
400,800,1400	
	
	
No	
	
	
Multi-b	value,	
ADC	&	high	b	
	
3mm	
	
2.0x2.0x3.6mm	
	
0,50,400,	
800,1200	
	
No	
	
	
Multi-b	value	&	
ADC	
	
6mm	
	
1.89x1.89x6mm	
	
0,500,1000,	
2000	
	
Yes	
	
	
Multi-b	value,	
ADC	&	high	b	
	
4mm	
	
3.1x3.1x4mm	
	
0,50,100,150,	
200,250,800,	
1000,1500,4000	
No	
	
Multi-b	value,	
ADC	
&	high	b	
	
3mm	
	
3x3x3mm	
	
1,50,150,300,	
800,	2000	
	
No	
	
Multi-b	value	&	
ADC	
	
	
3mm	
	
1.4x1.4x3mm	
Bowel	Relaxant	 Yes	 Yes	 Yes	 No	 Yes	 Yes	 Yes	
PPA		=	pelvic	phased	array,		ER	=	endorectal,	Res.	=	resolution,	DCE	=	dynamic	contrast	enhanced,	DWI	=	diffusion	weighted	imaging,	s	=	second,	NR	=	not	reported	
13	
	
Table	S4:	Clinician	experience		
The	following	table	details	the	experience	of	the	clinicians	involved	in	PRECISION	trial	
procedures	at	the	start	of	the	trial	
	
Clinician	category	 Total	
number	
in	study	
Experience	of	individual	clinicians	prior	to	starting	study	
Descriptor	of	experience	 Median	number,	n	(IQR)	
Transrectal	
ultrasound	guided	
(TRUS)	biopsy	
operators	
	
38	 Number	of	TRUS	biopsies	
previously	performed			
	
Number	of	TRUS	biopsies	
performed	per	year	
750	(300-1000)		
	
	
100	(50-190)	
MRI-targeted	biopsy	
operators	
33	 Number	of	MRI-targeted	
biopsies	previously	performed			
	
Number	of	MRI-targeted	
biopsies	performed	per	year	
100	(28-250)	
	
	
60	(25-100)		
	
Radiologists	
reporting	MRI	
37	 Number	of	prostate	MRIs	
reported	per	year	
	
Number	of	years	of	experience		
300	(200-500)	
	
	
5	(4.5-10)	
Pathologists	
reporting	prostate	
specimens	
39	 Number	of	patient’s	prostate	
specimens	analyzed/year		
	
Number	of	years	of	experience		
230	(100-350)	
	
	
11	(8-20)	
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Table	S5:	Techniques	used	by	sites	for	MRI-targeted	prostate	biopsy	
 
Site	 No.	of	men	
randomized	to	
MRI±TB	arm	
Access	route	 Registration	used	 Name	of	software	assisted	
system	(where	applicable)	
1	 37	 Transrectal	 Visual	&	Software-assisted	 Philips	UroNav	
2	 31	 Transrectal	 Visual	&	Software-assisted	 UC-Care	Medical	Systems	
3	 31	 Transrectal	 Software-assisted	 Koelis	Urostation	
4	 27	 Transrectal	 Software-assisted	 Philips	UroNav	
5	 27	 Transrectal	 Software-assisted	 Koelis	Urostation	
6	 26	 Transrectal	 Software-assisted	 BK	Biojet	
7	 10	 Transperineal	 Visual	 N/A	
8	 10	 Transrectal	 Software-assisted	 Koelis	Urostation	
9	 7	 Transrectal	 Visual	 N/A	
10	 6	 Transrectal	 Software-assisted	 Koelis	Urostation	
11	 6	 Transperineal	 Visual	 N/A	
12	 4	 Transrectal	 Software-assisted	 Vnav	Esaote	
13	 5	 Transrectal	 Visual	&	Software-assisted	 Philips	UroNav	
14	 5	 Transperineal	 Visual	 N/A	
15	 4	 Transrectal	 Software-assisted	 Koelis	Urostation	
16	 3	 Transrectal	 Visual	 N/A	
17	 2	 Transrectal	 Software-assisted	 Philips	EPIQ	
18	 2	 Transperineal	 Visual	 N/A	
19	 2	 Transrectal	 Software-assisted	 Toshiba	Medical	Aplio	500	
20	 2	 Transrectal	 Software-assisted	 Philips	UroNav	
21	 2	 Transrectal	 Software-assisted	 Eigen	Artemis	
22	 2	 Transperineal	 Software-assisted	 Medcom	BiopSee	
23	 1	 Transrectal	 Software-assisted	 Koelis	Urostation	
MRI±TB	=	MRI±targeted	biopsy;	Software-assisted	=	MRI/US	fusion	
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Table	S6:	Secondary	outcomes	in	the	study1	
 
Outcome	 Time	frame	for	assessment	&	further	details	
Proportion	of	men	with	clinically	insignificant	
cancer	(Gleason	grade	3+3)	
When	histology	results	available,	at	an	expected	
average	of	30	days	post-intervention	
Proportion	of	men	in	MPMRI	arm	who	avoid	biopsy	 When	MRI	results	available,	at	an	expected	average	
of	30	days	post-MRI	
Proportion	of	men	in	whom	MPMRI	score	for	
suspicion	of	clinically	significant	cancer	was	3,	4	or	5	
but	no	clinically	significant	cancer	was	detected	
When	histology	results	available,	at	an	expected	
average	of	30	days	post-biopsy	
Proportion	of	men	who	go	on	to	definitive	local	
treatment	(e.g.	radical	prostatectomy,	
radiotherapy,	brachytherapy)	or	systemic	treatment	
(e.g.	hormone	therapy,	chemotherapy)	
After	treatment	decision,	at	an	expected	average	of	
30	days	post-biopsy	
Cancer	core	length	of	the	most	involved	biopsy	core	
(maximum	cancer	core	length,	mm)	
When	histology	results	available,	at	an	expected	
average	of	30	days	post-intervention	
Proportion	of	men	with	post-biopsy	adverse	events	 30	days	post-biopsy	
Health	related	quality	of	life	 Baseline,	24	hours	post	intervention	and	30	days	
post	intervention	
Proportion	Gleason	grade	upgrading	in	men	
undergoing	radical	prostatectomy	
An	expected	average	of	90	days	post-biopsy	
Cost	per	diagnosis	of	cancer	
	
An	NHS	health	services	perspective	was	taken	for	a	
cost-effectiveness	analysis	assessing	the	within-arm	
costs	of	the	diagnostic	tests,	staging	tests	and	health	
care	contacts	within	30-days	in	relation	to	numbers	
of	clinically	significant	and	insignificant	cancers	
detected	within	that	arm	
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Table	S7a,b,c:	Derivation	of	the	Intention	to	treat,	modified	intention	to	treat	and	
per	protocol	analyses	of	the	primary	outcome	
	
These	tables	were	derived	in	the	statistical	analysis	plan,	finalised	prior	to	obtaining	the	
data	from	the	study	
	
Table	S7a:	Randomized	allocation	and	analysis	group	for	intention-to-treat	analysis	
Test	allocated	 Test	received	 Analysis	group	
TRUS	biopsy	 TRUS	biopsy	 TRUS	biopsy	
TRUS	biopsy	 MRI	(score	1	or	2)	and	no	biopsy	 TRUS	biopsy	
TRUS	biopsy	 MRI	(score	3,	4	or	5)	and	MRI-TB	 TRUS	biopsy	
TRUS	biopsy	 Other	 TRUS	biopsy	
MRI±TB		 TRUS	biopsy		 MRI	
MRI±TB	 MRI	(score	1	or	2)	and	no	biopsy	 MRI	
MRI±TB	 MRI	(score	3,	4	or	5)	and	MRI-TB	 MRI	
MRI±TB	 Other	 MRI	
		MRI±TB	=	MRI±targeted	biopsy,	TRUS	=	Transrectal	ultrasound	guided	
	
	
Table	S7b:	Comparisons	of	intention-to-treat,	modified	intention-to-treat	and	per-
protocol	analyses	for	TRUS	biopsy	arm.	Conditions	for	excluding	patients	based	on	
deviations	from	the	protocol.	
Randomization	
arm	
Diagnostic	test	received	 Action	
for	ITT	
analysis	
Action	for	
modified	
ITT		
Action	for	
per-protocol	
analysis	
TRUS	biopsy	 Other	diagnostic	test	 Include	 Include	 Exclude	
TRUS	biopsy	 MRI	(score	1	or	2)	and	no	
biopsy	
Include	 Include	 Exclude	
TRUS	biopsy	 MRI	(score	3,	4	or	5)	and	
MRI-TB	
Include	 Include	 Exclude	
TRUS	biopsy	 MRI	(score	1	or	2)	but	still	has	
other	biopsy	
Include	 Include	 Exclude	
TRUS	biopsy	 MRI	(score	3,	4	or	5)	but	
other	biopsy	
Include	 Include	 Exclude	
TRUS	biopsy	 TRUS	biopsy	but	with	
deviation	in	biopsy	core	
number	greater	than	±	10%	
Include	 Include	 Exclude	
TRUS	biopsy	 Withdrawn	prior	to	any	fully	
completed	diagnostic	test		
Include		 Exclude	 Exclude	
	ITT,	intention-to-treat;	MRI±TB	=	MRI±targeted	biopsy,	TRUS	=	Transrectal	ultrasound	guided	
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Table	S7c:	Comparisons	of	intention-to-treat,	modified	intention-to-treat	and	per	protocol	
analyses	for	MRI±TB	arm.	Conditions	for	excluding	patients	based	on	deviations	from	the	
protocol.	
Randomization	arm	 Diagnostic	test	received	 Action	for	
ITT	analysis	
Action	for	
modified	ITT		
Action	for	
per-protocol	
analysis	
MRI±TB	 TRUS	biopsy	 Include	 Include	 Exclude	
MRI±TB	 Other	biopsy	test	 Include	 Include	 Exclude	
MRI±TB	 Attempted	but	incomplete	MRI	
(e.g.	because	patient	could	not	
tolerate	full	MRI)	followed	by	
TRUS	biopsy	or	other	biopsy	test	
Include	 Include	 Exclude	
MRI±TB	 MRI±TB	but	MRI	not	multi-
parametric	(e.g.	contrast	or	
diffusion	weighted	sequences	
not	taken)	
Include	 Include	 Exclude	
MRI±TB	 MRI	(score	3,	4	or	5)	and	MRI-TB	
but	with	deviation	in	biopsy	core	
number	greater	than	±	10%	
Include	 Include	 Exclude	
MRI±TB	 MRI	(score	3,	4	or	5)	and	MRI-TB	
but	with	additional	biopsy	test	at	
same	sitting	
Include	 Include	 Exclude	
MRI±TB	 MRI	(score	3,	4	or	5)	and	MRI-TB	
but	where	not	all	of	MRI-
suspicious	areas	were	targeted	
e.g.	3	suspicious	areas	identified	
but	only	1	targeted	
Include	 Include	 Exclude	
MRI±TB	 MRI	(score	3,	4	or	5)	but	no	
biopsy	
Include	 Exclude	 Exclude	
MRI±TB	 MRI	(score	3,	4	or	5)	but	other	
type	of	biopsy	
Include	 Include	 Exclude	
MRI±TB	 Withdrawn	prior	to	any	fully	
completed	diagnostic	test		
Include	 Exclude	 Exclude	
		ITT,	intention-to-treat;	MRI±TB	=	MRI±targeted	biopsy,	TRUS	=	Transrectal	ultrasound	guided		
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Table	S8:	MPMRI	features	
Characteristic	 MRI±TB	
(N	=	246)*	
Field	strength	of	magnet	—	no.	(%)	 	
1.5T		 62	(25.2)	
3.0T		 184	(74.8)	
MRI	suspicion	score	—	no.	(%)	 	
1–2	 71	(28.9)	
3,	4	or	5	 175	(71.1)	
Suspicious	lesions	per	patient	—	no.	(%)†	 	
1	lesion	 107	(61.1)	
2	lesions	 44	(25.1)	
3	lesions	 24	(13.7)	
Highest	MRI	score	for	men	with	suspicious	lesions‡	—	no.	(%)				 	
Score	3	 51	(29.1)	
Score	4	 70	(40.0)	
Score	5	 54	(30.9)	
MRI	volume	of	prostate§	—	mls	 	
Median	(IQR)	 46.0	(34.9	to	62.0)	
Problems	with	MR	quality	—	no.	(%)				 13	(5.3)	
Median	maximum	lesion	diameter	(lesion-based)∆	—	mm	 	
Median	(IQR)	 12	(8	to	15)	
Median	lesion	volume	(lesion-based)∆	—	mls	 	
Median	(IQR)	 0.6	(0.3	to	1.2)	
	 	
MPMRI	=	Multiparametric	MRI,	MRI±TB	=	MRI±targeted	biopsy	 	
*Six	of	the	patients	in	the	MRI	arm	were	protocol	violators	with	no	MRI	data.	Therefore,	the	number	of	
patients	is	246	unless	indicated	otherwise.	
†Percentages	are	based	on	the	175	men	with	MRI	suspicion	score	of	3,	4,	or	5.	
‡Each	patient	may	have	more	than	one	suspicious	lesion.	The	highest	MRI	score	for	each	of	the	175	
patients	with	at	least	one	suspicious	lesion	was	included	so	that	each	patient	contributed	only	one	score.	
§Prostate	volume	was	unknown	for	one	man	and	so	the	results	are	based	on	245	men.	
∆Calculated	using	all	lesions	for	each	patient	(lesion-based).		
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Table	S9:	Biopsy	characteristics	for	men	undergoing	MRI-TB	and	TRUS	biopsy	
	 MRI-TB	
(N	=	169)	
TRUS	biopsy	
(N	=	228)	
TRUS	volume	of	prostate	—	mls		 	 	
Median	(IQR)	 40.5	(32.0–54.8)	 43.7	(33.3–60.0)	
	
Number	of	biopsies	taken		
	 	
Median	(IQR)	 4	(3	to	7)	 12	(12	to	12)	
	
Length	of	procedure	—	mins*	
	 	
Median	(IQR)	 15	(10	to	25)	 10	(9	to	15)	
	
Anaesthetic	—	no.	(%)	
	 	
Local	 114	(67.5)	 196	(86.0)	
Sedation/general	anaesthetic/spinal	 55	(32.5)	 32	(14.0)	
	 	 	
*Length	of	procedure	based	on	time	from	when	TRUS	probe	inserted	prior	to	procedure	to	when	TRUS	
probe	removed	at	end	of	procedure	
MRI-TB	=	MRI-targeted	biopsy,	TRUS	=	Transrectal	ultrasound	guided	
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Table	S10:	Health-related	quality	of	life	at	baseline,	24	hours	post	intervention	and	30	days	post	intervention	
	
Variable	 Baseline	 	 24	hours	 	 Mean	difference		
(95%	CI)	
P	
value	
	 30	days	 	 Mean	difference		
(95%	CI)	
P	
value	
	 MRI±TB*	
(N	=	245)	
TRUS-biopsy	
(N	=	238)	
	 MRI±TB*	
(N	=	215)	
TRUS-biopsy	
(N	=	200)	
	 	 	 	 MRI±TB*		
(N	=	200)	
TRUS-biopsy	
(N	=	192)	
	 	 	
EQ-5D	
descriptive	
score	
0.909±0.137	 0.907±0.123	 	 0.907±0.126	 0.894±0.159	 	 0.006		
(-0.017	to	0.029)	
0.61	 	 0.917±0.124	 0.921±0.126	 	 -0.004		
(-0.028	to	0.020)	
0.72	
EQ-5D	VAS	
score	
85.6±11.8	 85.5±10.2	 	 84.8±10.8	 84.2±11.3	 	 0.61		
(-0.95	to	2.18)	
0.44	 	 84.6±11.9	 85.7±10.3	 	 -0.27		
(-1.88	to	1.33)	
0.74	
Plus–minus	values	are	means	±SD.	MRI±TB	=	MRI±targeted	biopsy,	TRUS	=	Transrectal	ultrasound	guided.	
*If	the	patient	only	underwent	MRI	and	did	not	undergo	biopsy,	the	24-hour	and	30-day	post	intervention	questionnaires	refer	to	the	post	MRI	
questionnaires.	If	the	patient	underwent	MRI	and	targeted	biopsy,	the	questionnaires	refer	to	the	post-biopsy	questionnaires.	Scores	from	the	domains	of	
the	European	Quality	of	Life	5	Dimensions	5-Level	(EQ-5D-5L)	Questionnaire	were	converted	to	EQ-5D	descriptive	scores	using	the	value	set	for	the	United	
Kingdom.		Scores	from	the	EQ	visual	analogue	scale	(VAS)	were	also	summarised.	Higher	EQ-5D	scores	indicate	better	quality	of	life.	For	the	comparison	of	
the	two	arms,	mean	differences	(value	in	the	MRI±TB	arm	minus	value	in	the	TRUS	biopsy	arm)	were	estimated	using	repeated	measures	mixed	models	
with	adjustment	for	baseline	levels.	
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Table	S11:	Post-intervention	patient-reported	complications	
	
	 MRI±TB*	 TRUS	biopsy	 	
Immediate	post-intervention	complications†	
	
Discomfort		
(N	=	224)										(N	=	222)	
							
	
Median	(IQR)	 2	(0–4)	 3	(2–5)	
Pain		 	 	
Median	(IQR)	 1	(0–3)	 2	(1–4)	
	 	 	
30-day	post-intervention	complications		 (N	=	212)										(N	=	206)	
	 								No.	of	patients	(%)	
	
Fever	
	
9	(4.2)	
	
9	(4.4)	
Blood	in	the	urine	 64	(30.2)	 129	(62.6)	
Blood	in	the	semen	
Blood	in	the	stools	or	from	the	back	passage	
Acute	urinary	retention	
Erectile	dysfunction	
Urinary	incontinence	
Urinary	tract	infection	
Pain	at	site	of	procedure	
Men	for	whom	another	procedure	would	be	a	major	
problem	
68	(32.1)	
30	(14.2)	
3	(1.4)	
23	(10.8)	
13	(6.1)	
5	(2.4)	 	
27	(12.7)	
2	(0.9)	
123	(59.7)	
45	(21.8)	
2	(1.0)	
32	(15.5)	
10	(4.9)	
2	(1.0)	 	
48	(23.3)	
10	(4.9)	
	 	 	
MRI±TB	=	MRI±targeted	biopsy,	TRUS	=	Transrectal	ultrasound	guided	
*If	the	patient	only	underwent	MRI	and	did	not	undergo	biopsy,	the	immediate	intervention	questionnaire	
refers	to	the	post	MRI	questionnaire.	If	the	patient	underwent	MRI	and	biopsy,	the	questionnaire	refers	to	
the	post-biopsy	questionnaire.	
†Based	on	a	numerical	analogue	scale	ranging	from	0	to	10,	with	higher	scores	indicating	greater	intensity	of	
symptoms.	
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Table	S12:	Investigator-reported	adverse	events	
	
Characteristic	 MRI±TB	
(N	=	252)	
N	(%)	
TRUS	biopsy	
(N	=	248)	
N	(%)	
Number	of	adverse	events	 	 	
		Serious	adverse	events	 4	(1.6)	 5	(2.0)	
		Adverse	events	 2	(0.8)	 3	(1.2)	
	
Adverse	events	related	to	intervention	
	 	
		Sepsis	 1	(0.4)	 4	(1.6)	
		Haematuria	 0	(0)	 1	(0.4)	
		Prostatitis	 3	(1.2)	 0	(0)	
	
Adverse	events	unrelated	to	intervention	
		Fatigue	 0	(0)	 1	(0.4)	
		Runny	nose	and	cough	 0	(0)	 1	(0.4)	
		Myocardial	infarction	 0	(0)	 1	(0.4)	
		Pulmonary	embolism	 1	(0.4)	 0	(0)	
		Death	(secondary	to	pulmonary	metastasis	of				
		known	squamous	cell	carcinoma)	 1	(0.4)	 0	(0)	
MRI±TB	=	MRI±targeted	biopsy,	TRUS	=	Transrectal	ultrasound	guided	 	
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Table	S13:	Proportion	of	men	undergoing	definitive	treatment	
	
 
MPMRI	=	Multiparametric	MRI,	MRI±TB	=	MRI±targeted	biopsy,	TRUS	=	Transrectal	ultrasound	
guided	
*A	patient	can	have	more	than	one	type	of	staging	scan.	Therefore,	the	percentages	were	calculated	
by	dividing	the	number	of	patients	who	received	the	scan	by	the	total	number	in	the	arm.	
	†Of	the	71	men	with	negative	MRI	and	no	biopsy,	3	(4.2%)	were	discharged,	62	(87.3%)	were	
referred	for	PSA	monitoring,	3	(4.2%)	underwent	further	prostate	biopsies	(all	were	negative),	1	
have	further	MPMRI	and	2	have	missing	information.	
  
Treatment	decision	 MRI±TB†		
(N	=252)	
N	(%)	
TRUS	biopsy		
(N	=	248)	
N	(%)	
Discharge	patient,	no	treatment	or	follow	up	required			 13	(5.2)	 15	(6.0)	
PSA	monitoring		 104	(41.3)	 74	(29.8)	
Active	Surveillance			 29	(11.5)	 29	(11.7)	
Radical	treatment	
		Radical	prostatectomy	
		Radiotherapy	±	neoadjuvant	hormone	therapy	
		Brachytherapy	
70	(27.0)	
34	(13.5)	
35	(13.9)	
1	(0.4)	
60	(24.2)	
30	(12.1)	
26	(10.5)	
4	(1.6)	
Focal	therapy			 1	(0.4)	 0	(0)	
Hormone	therapy	±	chemotherapy			 2	(0.8)	 2	(0.8)	
Watchful	waiting	 1	(0.4)	 2	(0.8)	
Other	treatment	decisions		 11	(4.4)	 7	(2.8)	
Unknown	 14	(5.6)	 20	(8.1)	
Further	diagnostic	tests	ordered	from	treatment	
decision	visit	
		MPMRI	for	diagnosis	
					Patient	choice	
					Clinician	choice	
		Immediate	further	prostate	biopsies	
					Patient	choice	
					Clinician	choice	
	
7	(2.7)	
3	(1.2)	
0		
3		
4	(1.6)	
1	
3		
	
39	(15.7)	
38	(15.3)		
1	
37	
1	(0.4)	
0	
1	
Further	staging	tests*		
		MRI	for	staging	
		Bone	scan	
		CT	
		PET-CT	
		PET-MRI	
	
2	(0.8)	
52	(20.6)	
33	(13.1)	
0	(0)	
0	(0)	
	
39	(15.7)	
37	(14.9)	
31(12.5)	
1	(0.4)	
1	(0.4)	
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Table	S14:	Outcomes	of	men	undergoing	further	diagnostic	procedures	following	
initial	protocol	test	
 
Characteristic	 MRI±TB	 TRUS	biopsy	
Further	MPMRI	following	treatment	decision	—	no.	 3	 38	
MPMRI	identified	suspicious	areas	scoring	3	or	greater	
—	no.	(%)	
		Yes	
		No	
	
	
0	(0)	
3	(100)	
	
	
18	(47.4)	
20	(52.6)	
MPMRI	with	post-biopsy	artefact	—	no.	(%)	 0	(0)	 7	(18.4)	
MPMRI	led	to	further	biopsy	—	no.		 0	(0)	 8	
Further	biopsies	following	treatment	decision	—	no.(%)	
		Transperineal	template	biopsy	
		10-12	core	transrectal	biopsy	
		MRI-targeted	prostate	biopsy	
4	
0	(0)	
3	(75.0)	
1	(25.0)	
9	
1	(11.1)	
0	(0)	
8	(88.9)	
Overall	Gleason	grade	from	further	biopsy	—	no.	(%)	
		Benign	
		ASAP	
		3+3	
		3+4	
	
3	(75.0)		
1	(25.0)	
0	(0)	
0	(0)	
	
5	(55.6)	
0	(0)	
1	(11.1)	
3	(33.3)	
Maximum	cancer	core	length	—	mm	
		Median	(IQR)	
	
NA	
	
6.5	(4.0	to	8.5)	
NA	=	not	applicable,	MPMRI	=	Multiparametric	MRI,	MRI±TB	=	MRI±targeted	biopsy,	TRUS	=	
Transrectal	ultrasound	guided	
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Table	S15:	Gleason	grade	concordance	with	original	biopsy	after	radical	
prostatectomy	
	
Number	of	cases		 Concordant	 Upgraded	 Downgraded	
MRI±TB	arm	-	no.	(%)	
	
19	(63.3)	 5	(16.7)	 6	(20.0)	
TRUS	biopsy	arm	-	no.	(%)	
	
19	(70.4)	 4	(14.8)	 4	(14.8)	
MRI±TB	=	MRI±targeted	biopsy,	TRUS	=	Transrectal	ultrasound	guided.	Results	of	radical	
prostatectomy	were	available	for	30	of	the	34	men	in	the	MRI±TB	arm	and	27	of	the	30	men	in	the	
TRUS	biopsy	arm.	The	remainder	were	lost	to	follow	up.	
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Table	S16a,b,c:	Quality	control	results	
	
Table	S16a:	Agreement	in	PIRADSv2	score	for	MPMRI	scans	between	site	reading	and	
central	quality	control	reading:	
 
	 	
PIRADsv2	score	for	MRI	as	reported	
centrally*	
	 	
1	 2	 3	 4	 5	 TOTAL	
PIRADSv2	
score	for	
MRI	
reported	
by	local	
site	
radiologist	
1	 10	 -	 1	 4	 -	 11	
2	 -	
	
5	
	
-	 1	 -	 10	
3	 1	
	
6	
	
2	 1	 1	 11	
4	 1	 -	 -	
	
8	
	
5	 14	
5	 -	 -	 1	
	
2	
	
15	 18	
TOTAL	 12	 11	 4	 16	 21	 64	
*25%	of	the	MRIs	from	every	site	were	chosen	at	random	and	were	reported	blinded	to	the	original	
report	by	two	expert	uro-radiologists	in	consensus	at	the	coordinating	centre	(one	with	15	years	of	
experience	and	one	with	5	years	of	experience	in	reporting	prostate	MRI,	both	reporting	
approximately	1000	scans	per	year)	
 
Key:	
	Concordant	scores,	where	management	decision	to	perform	biopsy	would	not	have	changed	
	Discordant	scores,	where	management	decision	to	perform	biopsy	would	have	changed	
	
Agreement	by	concordant	biopsy	decision:	50/64	=	78%	
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Table	S16b:	Agreement	in	Gleason	grade	score	for	men	undergoing	biopsy	between	site	
reading	and	central	quality	control	reading:	
	
	 	
	 Overall	Gleason	grade	by	central	pathology	review*	 	
	 	
Benign	 Gleason	3+3	
Gleason	
3+4	
Gleason	
3+5	
Gleason	
4+3	
Gleason	
4+4	
Gleason	
4+5	 TOTAL	
Overall	
Gleason	
grade	as	
reported	
by	local	site	
pathologist	
Benign	 26	 1	 1	 -	 -	 -	 -	 27	
Gleason	
3+3	 -	 8	 1	 -	 -	 -	 -	 9	
Gleason	
3+4	 -	 1	 13	 -	 -	 -	 -	 15	
Gleason	
3+5	 -	 -	 -	 1	 -	 -	 -	 0	
Gleason	
4+3	 -	 -	 1	 -	
	
1	
	
-	 -	 2	
Gleason	
4+4	 -	 -	 -	 -	 1	 1	 -	 2	
Gleason	
4+5	 -	 -	 -	 -	 -	 -	 3	 3	
Gleason	
5+4	 -	 -	 -	 -	 -	 -	 1	 1	
TOTAL	 25	 10	 16	 1	 2	 1	 4	 60	
*15%	of	biopsy	slides	from	every	site	were	chosen	at	random	and	reported	centrally	blinded	to	the	
original	report	by	one	of	4	uro-pathologists	based	at	the	coordinating	centre.	The	central	
pathologist’s	experience	in	reporting	prostate	specimens	was	23,	14,	8	and	3	years,	reporting	100,	
100,	100	and	250	prostate	specimens	per	year,	respectively)	
 
Table	S16c:	Summary	table	of	central	pathology	review	outcome:	
	 In	Agreement	 Upgraded	 Downgraded	
Number	of	cases		 53/60	(88%)	 3/60	(5%)	 4/60	(7%)	
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